-transparent.png){kind=logo}
To clarify the functional characteristics of prolactin (Prl)-producing adenoma cells, the effect of TRH, prostaglandin E1 (PGE1), theophylline, dopamine and dopaminergic antagonists on Prl secretion was examined in vitro in perifused pituitary adenoma tissues obtained at surgery from 8 patients with prolactinoma. Perifusion with TRH at a concentration of 10(-6) to 10(-5) M resulted in a significant increase in effluent Prl levels in 3 of the 8 adenoma tissues. In the remaining 5 adenomas, TRH produced no effect on Prl release in vitro. On the other hand, PGE1 (10(-5) M) stimulated Prl secretion in 2 of the 4 adenomas examined. Addition of theophylline (5.5 mM) caused a marked increase of effluent Prl levels in all 8 prolactinomas regardless of the reactivity to TRH or PGE1. Dopamine (5 X 10(-7) M) suppressed Prl secretion from adenoma tissue in 5 of 7 patients tested but had no effect in the remaining two adenomas. When perifused simultaneously with dopamine, sulpiride (D2-selective dopamine receptor blocker, 5 X 10(-7) M) blocked the inhibitory effect of dopamine on Prl release in 3 of the 4 dopamine-sensitive prolactinomas. In one adenoma responsive to dopamine but resistant to sulpiride, YM-09151-2 (relatively specific D1-dopamine receptor blocker, 5 X 10(-7) M) antagonized the dopaminergic inhibition of Prl release. When perifused alone, neither sulpiride nor YM-09151-2 affected Prl release from any of the adenoma tissues tested.(ABSTRACT TRUNCATED AT 250 WORDS)
K Chihara, and
J Iwasaki, and
N Minamitani, and
H Kaji, and
H Kodama, and
T Fujita, and
K Shirataki, and
N Tamaki, and
S Matsumoto
January 1993,
Life sciences,
K Chihara, and
J Iwasaki, and
N Minamitani, and
H Kaji, and
H Kodama, and
T Fujita, and
K Shirataki, and
N Tamaki, and
S Matsumoto
February 1988,
European journal of pharmacology,
K Chihara, and
J Iwasaki, and
N Minamitani, and
H Kaji, and
H Kodama, and
T Fujita, and
K Shirataki, and
N Tamaki, and
S Matsumoto
May 2012,
Molecular and cellular endocrinology,
K Chihara, and
J Iwasaki, and
N Minamitani, and
H Kaji, and
H Kodama, and
T Fujita, and
K Shirataki, and
N Tamaki, and
S Matsumoto
January 2022,
Frontiers in endocrinology,
K Chihara, and
J Iwasaki, and
N Minamitani, and
H Kaji, and
H Kodama, and
T Fujita, and
K Shirataki, and
N Tamaki, and
S Matsumoto
July 1986,
The Tohoku journal of experimental medicine,
K Chihara, and
J Iwasaki, and
N Minamitani, and
H Kaji, and
H Kodama, and
T Fujita, and
K Shirataki, and
N Tamaki, and
S Matsumoto
August 1990,
Endocrinology,
K Chihara, and
J Iwasaki, and
N Minamitani, and
H Kaji, and
H Kodama, and
T Fujita, and
K Shirataki, and
N Tamaki, and
S Matsumoto
September 2010,
General and comparative endocrinology,
K Chihara, and
J Iwasaki, and
N Minamitani, and
H Kaji, and
H Kodama, and
T Fujita, and
K Shirataki, and
N Tamaki, and
S Matsumoto
January 1974,
Polish journal of pharmacology and pharmacy,
K Chihara, and
J Iwasaki, and
N Minamitani, and
H Kaji, and
H Kodama, and
T Fujita, and
K Shirataki, and
N Tamaki, and
S Matsumoto
December 1983,
Endocrinology,
K Chihara, and
J Iwasaki, and
N Minamitani, and
H Kaji, and
H Kodama, and
T Fujita, and
K Shirataki, and
N Tamaki, and
S Matsumoto
August 1974,
Endocrinology,
